Notice2022-12950

National Institute on Drug Abuse; Notice of Closed Meeting

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
June 16, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 116 (Thursday, June 16, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 116 (Thursday, June 16, 2022)]
[Notices]
[Page 36335]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12950]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research 
(R21 Clinical Trial Optional).
    Date: July 25, 2022.
    Time: 2:00 p.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Research, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC, 
6021, Bethesda, MD 20892, (301) 594-9460, <a href="/cdn-cgi/l/email-protection#6c3f0315031902420f04032c020504420b031a"><span class="__cf_email__" data-cfemail="c596aabcaab0abeba6adaa85abacadeba2aab3">[email&#160;protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: June 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-12950 Filed 6-15-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on June 16, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.